Novartis Investigative Site

Szombathely H-9700

0 studies enrolling now · 12 studies all time

What they study most

Acute Heart Failure, Adrenocortical Adenoma, Asthma, Cancer, Carcinoma, Carcinoma, Renal Cell, Chronic Obstructive Pulmonary Disease (COPD), Chronic Plaque Psoriasis, Early Breast Cancer, Endometrial Stromal Sarcomas, Moderate to Severe Plaque-type Psoriasis, Partial Onset Seizures

Studies at this site

• A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer — Running, not enrolling
• Phase II BGG492 Capsule Extension for Partial Epilepsy — Completed
• Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis — Completed
• Efficacy and Safety of BGG492 as Adjunctive Treatment in Patients With Partial Onset Seizures — Completed
• A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) — Completed
• Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma — Completed
• A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma — Completed
• Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab — Completed
• Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF — Completed
• Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 — Completed
• Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma. — Completed
• A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation — Completed